Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Malignant Disease × Etoposide × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Lymphoma 160 Leukemia 98 Lymphoma, Large B-Cell, Diffuse 93 Precursor Cell Lymphoblastic Leukemia-Lymphoma 90 Lymphoma, Non-Hodgkin 90 Leukemia, Myeloid, Acute 74 Hodgkin Disease 72 Lymphoma, Follicular 62 Burkitt Lymphoma 58 Lymphoma, Mantle-Cell 55 Lymphoma, Large-Cell, Immunoblastic 54 Small Cell Lung Carcinoma 45 Leukemia, Lymphocytic, Chronic, B-Cell 42 Lung Neoplasms 41 Neuroblastoma 40 Lymphoma, B-Cell, Marginal Zone 33 Congenital Abnormalities 32 Multiple Myeloma 30 Sarcoma 26 Recurrence 26 Central Nervous System Neoplasms 26 Leukemia, Myelomonocytic, Acute 24 Leukemia, Monocytic, Acute 24 Leukemia, Erythroblastic, Acute 24 Carcinoma, Non-Small-Cell Lung 24 Myelodysplastic Syndromes 23 Testicular Neoplasms 22 Lymphoma, Large-Cell, Anaplastic 22 Leukemia, Megakaryoblastic, Acute 22 Brain Neoplasms 22

Interventions

amuvatinib 1 Topotecan 1 Paclitaxel 1 Etoposide 1 Erlotinib Hydrochloride 1 Docetaxel 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00881166 2024-08-02

SGI-0470-02

Astex Pharmaceuticals, Inc.

Phase 1 Completed

Malignant Disease

Data powered by HemOnc (CC BY 4.0) Colophon ⚡